Affiliate links on our site may earn us commissions. Learn More.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy Policy.

arrow
Newsletter

Discover The Best Wellness Tips In Your Inbox

Subscribe to Health Reporter’s newsletter and get our health experts’ highlights and the latest news about healthy living.
The newsletters are spam-free and sent from our health experts and professionals.
sent

Thank You!

You have successfully subscribed to our newsletter!
Home arrow News arrow Breakthrough Weight Loss Jab: Tirzepatide Shows Big Results

Breakthrough Weight Loss Jab: Tirzepatide Shows Big Results

HealthReporter author Nadzeya Sankovich
Written by Nadzeya Sankovich
Last update: October 16, 2023
1 min read 615 Views 0 Comments
clock 1 eye 615 comments 0
Breakthrough Weight Loss Jab - Tirzepatide Shows Big Results

Key Takeaways:

  • A new jab called Tirzepatide is showing promise in helping people lose a significant amount of weight.
  • In a study, those who used Tirzepatide lost almost a fifth more weight compared to those who didn’t.

A once-weekly injection hailed as the “King Kong” of weight loss jabs, Tirzepatide showed promise in helping people shed nearly a fifth of their body weight.

Last month, the National Institute for Health and Care Excellence recommended Tirzepatide for people with type 2 diabetes intolerant to metformin. However, its appetite-suppressing properties position it as a potent tool in the fight against obesity, surpassing other drugs such as semaglutide.

A recent study, led by Professor Thomas Wadden from the University of Pennsylvania and published in the journal Nature Medicine, focused on 287 participants who had successfully lost at least 5% of their weight through diet and exercise.

Individuals in this category often regain about a third of their lost weight. However, those who received Tirzepatide saw an additional average reduction of 18.4% in body weight over the course of a year.

Professor Wadden said that “Slimmers often hit a wall, where they cannot get beyond losing five to 10 per cent of their weight – but this drug could help them achieve substantially more.”

The drug provided benefits beyond weight loss, including reductions in blood pressure and cholesterol levels, as well as improved blood sugar control.

The pharmaceutical giant Eli Lilly, the manufacturer of Tirzepatide, funded the trial. In the fight against excess weight, Tirzepatide is emerging as a promising contender and offers hope for those struggling with conventional weight loss strategies.

Nonetheless, the study acknowledges the potential side effects of nausea, diarrhea, and constipation, which were mitigated by gradually introducing the Tirzepatide dose over four months. Weight loss jab critics warn about potential long-term risks, saying more research is needed into their safety and effectiveness.

Sources

Allen, V. (2023, October 16). The fat jab that can help you lose a fifth of your weight – Tirzepatide is hailed as the “King Kong”. . . Mail Online.
https://www.dailymail.co.uk/health/article-12633747/The-fat-jab-help-lose-fifth-weight-Tirzepatide-hailed-King-Kong-anti-obesity-treatment.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

Written by Nadzeya Sankovich
Nadzeya Sankovich is the Vice President of Communications at Health Reporter. Previously a professional journalist, she continues to write scientific articles and conduct research. With a background in sociology and medicine, she has worked with various healthcare organizations, from charities to telemedicine platforms.

Nadzeya is also a member of the Association of Health Care Journalists and a volunteer for a non-profit organization that helps underserved communities. Through her work, she empowers people to take charge of their health and well-being.
Was this article helpful?
check
Thank you! We received Your feedback
0 Comments

Leave a comment

checked
Thank you for your comment!
We will review it as soon as possible.
HealthReporter
Your Name
Missing required field
Your Comment
Missing required field

company-logo